Navigation Links
Trial Of DMD Gene Therapy Initiated At Ohio

Jerry Mendell a neurologist, co-director of the Muscular Dystrophy Association (MDA) clinic at Columbus Children’s Hospital; professor of pediatrics, neurology and pathology at Ohio State University College of Medicine;// and head of the Neuromuscular Research Program and Gene Therapy Center at Columbus Children’s Research Institute. He administered an injection of Asklepios Biopharmaceutical Inc (AskBio’s) Biostrophin, which contains a functional gene for the muscle protein dystrophin, into the biceps of Andrew Kilbarger, 8, of Lancaster, Ohio.

He initiated the first U.S. human gene therapy trial directed at Duchenne muscular dystrophy (DMD) at Columbus (Ohio) Children’s Hospital. It is a long-awaited step in the overall plan to help kids with muscular dystrophy. He said that it is hoped by everyone that this effort will help guide us toward clinically meaningful results as we move forward with this form of treatment. Sharon Hesterlee, MDA Director of Research Development said that it was with great difficulty that this gene therapy trail was possible a sit had to overcome the scientific, technical and regulatory hurdles. The gene for dystrophin was identified in 1986 by MDA-supported researchers.

The transformation was very exciting from the academic institutions, where basic science concepts are developed into the industry, where concepts became products. She also said that it would not have been possible if Asklepios had not taken a big risk of combining business, academic and nonprofit players. Duchenne muscular dystrophy is a genetic disease that begins in early childhood, causes progressive loss of muscle strength and bulk, and usually leads to death at the age of 20 as a result of respiratory or cardiac muscle failure. This is due to the gene mutation on the X chromosome. This results in the failure of the production of the essential muscle protein dystrophin. This gene is the largest known gene. Hence it was with great effort that it w as miniatured while retaining at the same time the crucial elements of the DNA.

AskBio’s Biostrophin therapy delivers the miniaturized replacement dystrophin gene with the help of Biological Nano Particles (BNP). BNP’s carry the minidystrophin gene to muscle cells. The Food and Drug Administration gave the team a green light to proceed with the human trial on March 3. The trial will test six boys with DMD, each of whom will receive minidystrophin genes in a muscle of one arm and a placebo in the other arm. Neither the investigators nor the participants will know which muscle got the dystrophin genes. After several weeks, an analysis of the injected muscle tissue’s microscopic appearance, as well as extensive testing of the health and strength of the trial participants would confirm the effectiveness of the therapy.

Related medicine news :

1. Results Of Human Trials Of Hungarian Bird-Flu Vaccine Expected Today
2. Vaccine For Dengue Fever On Trial In Asia-Pacific
3. DNA Vaccine Trials Against HIV Virus In Sweden Nurture Hope
4. Clinical Trials of New Drug Febuxostat Show Promise in Gout Treatment
5. Sex, Race Influence Lung Cancer Trial Participation
6. Clinical Trials Of New Anti-Cancer Drug To Be Initiated In New Zealand
7. Diarrhea Vaccine Trials Promises Prevention of Rotavirus Infection
8. New Generation Clinical Trials Could Save Time And Money, Improve Patient Care
9. China Begins Human Trials For HIV/AIDS Drug
10. Patients Should Be Entitled to "Humane Compensation" if Drug Trials Go Wrong
11. HIV/AIDS Vaccine Trial To Be Initiated Soon
Post Your Comments:

(Date:11/24/2015)... ... November 24, 2015 , ... Dr. Todd S. Afferica, a noted general ... of his patients. Dr. Afferica now uses the BIOLASE WaterLase iPlus 2.0™ in many ... the doctor uses other traditional cutting tools, such as the scalpel and high-speed drill, ...
(Date:11/24/2015)... ... November 24, 2015 , ... In an article published November 12th ... which patients are or are not eligible for bariatric surgery. The article explains that ... are more than 100 pounds overweight, or have a BMI of 35 and over ...
(Date:11/24/2015)... ... 2015 , ... It takes only three to five seconds to make a ... first impression be positive and reflects business values. If a client starts with a ... to return. They will also share their thoughts about a business with others, which ...
(Date:11/24/2015)... ... 2015 , ... Cancer patients, survivors, caregivers, family members and ... taping of the next CURE Connections® video series on Saturday, Dec. ... at Georgetown University Hotel & Conference Center in Washington, D.C. , CURE Connections, ...
(Date:11/24/2015)... Danbury, CT (PRWEB) , ... November 24, 2015 , ... ... Network (WCHN) today announced an innovative study designed to yield insights into how to ... potential development of biomarkers for pancreatic cancer from small, non-coding RNA molecules (ncRNA), genetic ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... Nueva York , 24 de noviembre ... fabricante del Avery Breathing Pacemaker System, se complace ... MD; Ph.D. como consultor clínico. ... --> Foto -   ... doctor Jonzon es un fisiólogo y consultor en ...
(Date:11/24/2015)... 24, 2015 Avery Biomedical Devices (ABD), manufacturer ... announce the appointment of Anders Jonzon , MD; ... Dr. Jonzon is a Physiologist ... Hospital, Uppsala University, Uppsala and Children,s Hospital, Karolinska, ... a fellow at the Cardiovascular Institute (UCSF). His research ...
(Date:11/24/2015)... November 24, 2015 F1000Workspace - ... - since it was launched just six months ago. ... and authoring platform for scientists - since it was launched ... have been loaded on to F1000Workspace - a ... since it was launched just six months ago. ...
Breaking Medicine Technology: